Gilead plans to submit New Drug Application for Filgotinib to USFDA
Category: #health  | By Nikita Chaurasia  | Date: 2019-07-03 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Gilead plans to submit New Drug Application for Filgotinib to USFDA

Gilead Sciences, Inc., a biotechnology company recently provided an update about the investigational- filgotinib, selective JAK1 inhibitor, at a pre-NDA (New Drug Application) meeting with the USFDA, cite sources.

For the record, Gilead Sciences, Inc. is a US-based biotechnology firm that focuses on discovering, developing & commercializing innovative medicines in areas of medical needs that have been unmet. The company transforms & simplifies medical care for people with life-threatening illnesses across the world. The company is operational in more than 35 countries across the world and is headquartered in California.

Reportedly, the Phase 3 FINCH studies along with the ongoing Phase 2 MANTA safety study evaluating semen parameters with treatment of filgotinib in men with moderately to severely active ulcerative colitis or Crohn’s disease, were discussed by Gilead with the USFDA. As a result of the discussion, the company intends to submit the New Drug Application for filgotinib as a treatment for rheumatoid arthritis by this year.

The announcement came on the heels of announcement made earlier by Gilead Sciences to collaborate with Carna Biosciences to develop & commercialize small molecule compounds in immune oncology. The biotechnology companies have also entered into a research & development partnership to examine Carna Biosciences’ proprietary lipid kinase drug discovery platform.

As per the conditions pertaining to the license agreement, Gilead Biosciences will retrieve license from Carna Biosciences for rights to create & commercialize inhibitors against target of immuno-oncology target. In relation with this agreement, Carna Biosciences is expected to receive a payment of $20 million & is entitled to receive an additional payment of $450 million upon achievement of certain development & commercial milestones. Carna Biosciences is also expected to receive royalties on future net sales, report sources close to the matter.

Source credits: https://www.gilead.com/news-and-press/press-room/press-releases/2019/7/gilead-announces-intent-to-submit-new-drug-application-for-filgotinib-to-us-food-and-drug-administration-this-year

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

PM Liz Truss to launch comprehensive review of UK’s visa policy

PM Liz Truss to launch comprehensive review of UK’s visa policy

By Nikita Chaurasia

Newly appointed Prime Minister Liz Truss is considering doing a complete review of Britain's visa system, as the nation struggles with severe labor shortages in vital industries. Business leaders across the UK have reportedly praised the decision...

UAE: Entrepreneurs and investors can benefit from visa reforms

UAE: Entrepreneurs and investors can benefit from visa reforms

By Nikita Chaurasia

The visa and business reforms by the UAE will open new prospects for investors, entrepreneurs, IT specialists, job seekers, and tourists, according to credible sources. This will reportedly benefit the region’s economic growth. Business Link...

Flipkart introduces new tech and design upgrades ahead of holiday season

Flipkart introduces new tech and design upgrades ahead of holiday season

By Nikita Chaurasia

Flipkart, India's indigenous online marketplace, is reportedly offering customers an improved shopping experience on its widely popular app. To better serve various client groups that are exploring e-commerce during the holiday season, Flipkar...